CV Therapeutics has received Medlogics stock and is entitled to development milestone payments, royalties and other potential payments on future sales of any products incorporating the technology.
Louis Lange, chairman and CEO of CV Therapeutics, said: “Licensing our proprietary biopolymer stent-coating technology to Medlogics with its best-in-class stent design allows CV Therapeutics to potentially generate revenues from future milestones and product sales and to continue focusing on maximizing the potential for Ranexa, regadenoson and our pipeline of pharmaceutical therapies.”